Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|17|2933-2941

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.17, 2015-09, pp. : 2933-2941

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pazopanib: In Advanced Soft Tissue Sarcoma

By Deeks Emma D.  

Drugs, Vol. 72, Iss. 16, 2012-11 ,pp. : 2129-2140

Adis International

Access to resources Recommend Favorite

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

By Pacey Simon  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 481-488

Springer Publishing Company

Access to resources Recommend Favorite

Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life: Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled, Multicentre Clinical Trials

By Papp Kim A.  

Clinical Drug Investigation, Vol. 31, Iss. 1, 2011-01 ,pp. : 51-60

Adis International

Access to resources Recommend Favorite

Intensified chemotherapy for soft-tissue sarcoma

By  

Inpharma, Vol. 1, Iss. 1286, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

By Knowling M.   Blackstein M.   Tozer R.   Bramwell V.   Dancey J.   Dore N.   Matthews S.   Eisenhauer E.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 435-439

Springer Publishing Company

Access to resources Recommend Favorite